Culture Biosciences

Live from BioProcess International, it's Wednesday afternoon! Stop by booth #1245 to meet our team and see our 250mL and (recently launched!) 5L cloud-connected bioreactors.

Are you in Boston this week for the BioProcess International Conference & Exhibition? Visit us at booth #1245 to see our 250mL and 5L cloud-connected bioreactors in person!

Learn how you can use our next-gen digital bioreactor system to de-risk drug programs earlier in the pipeline and avoid constraints on lab infrastructure.

We're excited to announce the launch of our 5L cloud-connected bioreactors, which will enable our clients to generate material for product characterization, testing, and downstream processing development within our cloud platform. Check out this interview where we talk to CEO Will Patrick about this key milestone, and see how the 5L data is looking so far!

Launching Culture’s 5L Reactors: An Interview with CEO Will Patrick As we launch our 5L bioreactors, our co-founder and CEO Will Patrick reflects on why this is such a key milestone for Culture and our clients.

If you work on developing and improving new strains of microorganisms at a large biotech company, you've likely been in a situation where you need the bioreactor data from your last strain screening experiment to inform your next set of strain edits, but you don’t have the data in time.

Can you relate to this frustration? Now imagine you could get statistically significant strain screening data - instantly.

In our latest blog post, learn how you can accelerate your DBTL Cycle with a new strain screening paradigm.

Introducing a New Strain Screening Paradigm Accelerate your Design-Build-Test-Learn Cycle with a new strain screening paradigm. Get statistically significant strain screening data - instantly.

The cultured meat conversation continues...our CEO Will Patrick shares his ideas about three possible futures of cultured meat in this video from Seeker by The Verge. Check it out to hear his predictions and get a look into our cloud-connected bioreactor lab. https://hubs.ly/Q01hRdNg0

How one pig could feed a whole neighborhood for years In 2021, cultured meat companies raised $1.8 billion dollars in investment. But with so many roadblocks ahead and lots of different visions for the future, i...

Meet Shawn Lichaa, our Chief Administrative Officer and General Counsel. Before joining the team, Shawn was General Counsel at Curology. At Culture, Shawn oversees People, Facilities, Legal, Real Estate, Finance, and IT. He is excited to be working at Culture and helping our team fulfill a pressing need in the biomanufacturing industry. In another life, Shawn would have been a musician - he picked up the acoustic guitar at age 30 and taught himself the oud as a pandemic pastime. Welcome, Shawn!

Culture had its Netflix debut last week! Check out The Verge's new series, The Future Of, to see how fermentation and cell culture will impact the future of...cheeseburgers. We're excited to be featured along with UPSIDE Foods.

The Future Of, The Verge’s new show, is streaming on Netflix It’s like a documentary — for the future.

Meet the Director of Culture’s BAM Team, Diana Eng. Wondering what BAM is? Check out this interview with Diana to find out - and see how she leverages her experience in fermentation and tech transfer to support Culture’s clients.

From Tech Transfer to Data Analysis and Beyond: Culture’s BAM Team Partners with Clients from Scale-Down to Scale-Up Diana Eng is the director of Culture’s Bioprocess Alliance Management team. She uses her experience in fermentation and tech transfer to support our clients.

Our team loved seeing you all last week at Built With Biology and discussing how we can help scale synthetic biology with our cloud bioreactor platform.

A topic many of you were particularly interested in was scale-up and how to do it successfully. To learn more about how to mitigate risks associated with scaling up your bioprocess, check out our blog post: https://hubs.ly/Q018Kc_00

Have you stopped by our booth at Built With Biology yet? Come say hi to our team and learn how we're building the next generation of biomanufacturing infrastructure.

We're so excited to see everyone at Built With Biology next week! Stop by booth #2 to chat with our team and learn about a new digital journey in . Register here if you haven't yet: https://hubs.ly/Q017GYNf0

“A key opportunity I see for the industry is to create better alternatives to traditional meat. Using precision fermentation, we can produce ingredients like animal oils, collagen, and elastin, and then mix them into plant-based alternatives to achieve the texture and taste of real meat. Although prices of plant-based meat have decreased, adoption hasn’t increased much. This tells me we need to focus on R&D to make products taste more like the real thing” - Will Patrick, Co-founder and CEO, Culture Biosciences

Check out this article from Future Food-Tech on the biggest opportunities in the alternative protein industry.

Eight Opportunities Ripe for Growth in the Alternative Protein industry - Future Food-Tech Alternative Proteins Eight Opportunities Ripe for Growth in the Alternative Protein industry Pioneers across alternative protein sector continue to break new ground, launch new technologies and unlock key partnerships to enable scale-up. Future Food-Tech Alternative Proteins on June 21-22 will bring together senior deci...

Check out this article from The Spoon on the biomanufacturing capacity problem and what we’re doing at Culture to solve it. Thanks Michael Wolf for spreading the word!

As Future Food Companies Look to Grow, A New Crop of Startups Lend a Hand on Biomanufacturing Scale-up While companies creating precision fermented and cell-cultured food products continue to raise hundreds of millions of dollars in funding, the reality is their products are still years away from ma…

We are so excited to officially announce our partnership with Sestina Bio, who is making bioengineering a reality with their data-driven synthetic biology platform. Find out why Sestina's team opted to partner with Culture instead of purchasing and running an industry-standard bioreactor system.

Making Bioengineering a Reality: Culture Enables Sestina’s New SynBio Platform By using Culture, Sestina Bio has access to bioreactor capacity 1-2 years earlier than if they purchased the industry-standard system for their lab.

Hardware Engineer Collin Edington is (literally) building the future of Culture Biosciences - and has been since the beginning as our first employee. Read this interview with Collin to learn how Culture is scaling up in 2022 and about the new capabilities you can expect to see in our cloud bioreactors this year. https://hubs.ly/Q011DMQn0

How Culture Biosciences is Scaling Up: An Interview with Our First Employee An interview with Hardware Engineering Manager and first employee Collin Edington about the new capabilities you can expect from Culture's bioreactors.

With increasing consumer demand for alternatives to traditional animal products, what will the future of food production look like? Watch this panel discussion with the founders of Agronomics, SavorEat, and Culture Biosciences, including our CEO Will Patrick, and hear their opinions on the future of alternative proteins. https://hubs.ly/Q010-yBP0

New Alternatives to Animal Protein Jim Mellon, Co-Founder and Executive Director, Agronomics; Will Patrick, CEO and Co-Founder, Culture Biosciences; Racheli Vizman, Co-Founder and CEO, SavorEa...

Join Culture's CEO and co-founder Will Patrick for a panel discussion about the future of this Wednesday at 11:40 AM EST. Watch the live stream on Bloomberg or register for the event here: https://hubs.ly/Q010KXc_0

It’s no secret that biomanufacturing is booming. The challenge is there's a huge gap in the infrastructure required to manufacture bioproducts. Check out our latest blog post to find out how Culture is solving this problem.

The Global Biomanufacturing Capacity Problem With our cloud bioreactors, Culture is closing the gap in large-scale biomanufacturing capacity for clients looking to scale processes up to manufacturing.

Today, we at Culture Biosciences are thrilled to announce our $80M Series B financing. Our team is so excited for what’s to come as we tackle client demand for large-scale biomanufacturing, starting with 5L and 250L bioreactors. Thanks to Forbes, John Cumbers and team for sharing our story!

How Culture Biosciences Is Meeting The Demand For Large-Scale Biomanufacturing Today, Culture Biosciences, a technology company that offers an easier, faster, and cheaper way to do biomanufacturing research and development (R&D), announced Series B financing of $80 million.

We often hear this question from our clients developing a bioproduct for commercialization: when is the right time to transition to bioreactors? This next blog post series focuses on early-stage scenarios where bioreactors can be used to develop the framework for a project and accelerate progress at project stages often considered too early for bioreactors.


https://hubs.ly/H0Y68P40

When should I start using bioreactors? When developing a bioproduct, these are early-stage scenarios where bioreactors can be used to develop the framework for a project and accelerate progress.